Low-grade glioma

1 paper

In silico1

Trial sponsors

Day One Biopharmaceuticals
Company1 trialPhase 3418 people
Shanghai Fosun Pharmaceutical Industrial Development
Company1 trialPhase 3102 people
National Cancer Institute
2 trialsPhase 3335 people
Alicia Lenzen
1 trialPhase 395 people
University of California, San Francisco
2 trialsPhase 277 people
Emory University
1 trialPhase 2200 people
Barbara Ann Karmanos Cancer Institute
1 trialPhase 261 people
Dana-Farber Cancer Institute
1 trialPhase 223 people

Latest

2 in 12 months

Neuro-oncology Advances1 Jan

Cellular senescence escape and antiviral response discriminate glioblastoma from lower-grade gliomas

Experiments in cellsMechanisms

Frontiers in Aging8 Dec

Estimation of biological aging based on T-cell differentiation trajectories: emerging and future avenues

Computational studyBiomarkers

Signal Transduction and Targeted Therapy24 Jun

Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models

Experiments in cellsMechanisms

Nature Cancer8 May

A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis

Study in peopleMechanisms